Docosahexaenoic acid (DHA) incorporation into membrane phospholipids (DHA incorporation)

Docosahexaenoic acid (DHA) incorporation into membrane phospholipids is a fundamental biological process that regulates the biophysical properties of cellular membranes, especially within the central nervous system and retina (Stillwell & Wassall, 2003, Chem Phys Lipids). DHA is an omega-3 polyunsaturated fatty acid that is primarily integrated into the sn-2 position of phospholipids, such as phosphatidylcholine and phosphatidylethanolamine, through a deacylation-reacylation pathway known as the Lands cycle (Shindou & Shimizu, 2009, J Biol Chem). This process is mediated by specific enzymes, including long-chain acyl-CoA synthetases and lysophospholipid acyltransferases, and is facilitated in the brain by transporters like Mfsd2a (Nguyen et al., 2014, Nature). High levels of membrane-bound DHA enhance membrane fluidity, influence the function of transmembrane proteins like G protein-coupled receptors, and provide precursors for specialized pro-resolving mediators like neuroprotectin D1 (Bazan, 2006, Trends Neurosci). Clinically, maintaining or increasing DHA incorporation is a therapeutic goal in treating neurodegenerative diseases, cardiovascular disorders, and mood disorders, typically addressed through the administration of DHA-rich oils or ethyl esters (Calder, 2012, J Nutr). Monitoring of this process is often performed using the Omega-3 Index, which measures the percentage of DHA and EPA in red blood cell membranes (Harris & von Schacky, 2004, Prev Med).

Other names

DHA esterificationDHA phospholipid remodelingMembrane DHA enrichmentLands cycle DHA incorporation

Substrate supplementation increases the availability of DHA for enzymatic esterification into the sn-2 position of membrane phospholipids via the Lands cycle, mediated by acyl-CoA synthetases and lysophospholipid acyltransferases.